Risk factors

20/20 Biolabs (AIDX) risk factors

Item 1A of every 20/20 Biolabs, Inc. 10-K on file, and what changed from one year to the next.

Open AIDX in Gloomberb →
  • FY2025 10-K risk factors

    48 risks. Profitability achieved in 2021 and 2022 relied on COVID-19 testing that ceased in Q2 2023. Commercial success heavily depends on cancer screening and longevity tests. Operations face high risks regarding capital needs, regulatory changes like FDA LDT rules, and patent protection.

    Filed Mar 31, 2026